3176 results for «806»
3176 results
Built to last: lifetime management for durability and beyond
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the principles of lifetime management aimed at durability and optimal long-term outcomes in complex valvular heart disease cases. Key topics include the critical importance of initial valve choice, practical tips for optimizing paravalvular leak (PVL) management, and advanced strategies for redo transcatheter aortic...
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
Focused on mastering mitral transcatheter edge-to-edge repair (TEER), this session analyzed the 2025 ESC VHD guidelines and their clinical implications. It addressed optimal timing and treatment strategies for severe heart failure beyond the COAPT trial and explored technical solutions for complex anatomies, including customization approaches for...
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
Mastering techniques from basic to complex - TAVI basics
13 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a comprehensive overview of Transcatheter Aortic Valve Implantation (TAVI) fundamentals, focusing on CT scan analysis for optimal patient and valve selection, strategies to avoid procedural complications, and approaches to streamline TAVI procedures for improved outcomes.
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the mitral TEER masterclass focusing on unique anatomical challenges encountered in Asian populations. This session presents complex case studies illustrating device strategies and practical techniques aimed at minimizing complications and optimizing procedural outcomes in anatomically challenging scenarios.
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...
Miscellaneous complications: my worst nightmare
15 Feb 2026 – From PCR Tokyo Valves 2026
Explore the prevention and management of complications arising from transcatheter interventions in structural heart disease through challenging case analyses. This session presents real-world scenarios addressing complications encountered during TAVI, mitral, and tricuspid procedures, highlighting strategies to anticipate and manage these critical events effectively.
Procedural imaging for tricuspid valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Transcatheter valve-in-valve intervention: LIVE Educational Case from The Prince Charles Hospital, Metro North Health - Brisbane, Australia
14 Feb 2026 – From PCR Tokyo Valves 2026
Review a live educational case from The Prince Charles Hospital focused on transcatheter valve-in-valve intervention, highlighting anatomical challenges, critical CT imaging roles, and meticulous planning to prevent complications and ensure favorable outcomes.
A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death
18 May 2021
The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative...
EuroPCR 2025 – Meta-Analysis of Individual Patient Data from the PROTECTED TAVR and BHF PROTECT-TAVI Trials
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
